Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Anbinex** is a plasma-derived human antithrombin concentrate presented as a lyophilized powder for intravenous infusion in 500 IU and 1000 IU strengths. It functions as a serine protease inhibitor (serpin) that provides approximately 80% of thrombin inhibitory activity and also inactivates activated coagulation factors X, IX, VII, XI, and XII, with its anticoagulant effect significantly enhanced by heparin. Developed and manufactured by Grifols, it is primarily indicated for treating congenital antithrombin deficiency to prevent deep vein thrombosis and thromboembolic events, including perioperatively and postpartum, as well as for acquired antithrombin deficiency in various clinical settings.[1][2][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anbinex.